GlassScriptPhysician profile
Juan M Bernal
NPI 1003007980
$10,529.51
in general payments reported to CMS, 2019-2025
40 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $452 · 2021: $1,102 · 2022: $3,499 · 2023: $947 · 2024: $1,590 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,292 · Travel and Lodging: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.70 |
| Travel and Lodging | $1,244.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,944.60 | 2020-2025 | Triclip, Mitraclip, Navitor |
| Ancora Heart, INC. | $1,936.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,148.87 | 2019-2025 | |
| Edwards Lifesciences Corporation | $720.45 | 2020-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Inari Medical, INC. | $588.47 | 2019-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $384.15 | 2019-2024 | Xarelto |
| Abiomed | $297.38 | 2022-2024 | Impella |
| Celonova Biosciences, INC. | $296.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $224.96 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $216.27 | 2020-2024 | Opsumit, Uptravi |
| Amgen INC. | $175.28 | 2019-2022 | |
| Boston Scientific Corporation | $157.08 | 2020-2022 | |
| Pfizer INC. | $143.81 | 2019-2023 | |
| W. L. Gore & Associates, INC. | $123.76 | 2024-2025 | Gore Cardioform Septal Occluder, Gore Cardioform Asd Occluder |
| Cvrx, INC. | $115.77 | 2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.48 | 2019-2025 | Jardiance |
| Irhythm Technologies, INC. | $105.14 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $91.81 | 2021-2025 | Camzyos |
| Esperion Therapeutics, INC. | $82.92 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.42 | 2019-2025 | Lifevest |
| Biosense Webster, INC. | $76.00 | 2024 | Carto 3 |
| Novo Nordisk INC | $74.31 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $64.36 | 2019-2022 | |
| Medtronic, INC. | $63.28 | 2021-2024 | Symplicity G3, Abre |
| Bayer Healthcare Pharmaceuticals INC. | $44.16 | 2025 | |
| Amarin Pharma, INC. | $27.63 | 2019 | |
| Philips North America LLC | $23.79 | 2021 | |
| Csl Behring | $22.74 | 2021 | |
| Livanova USA, INC. | $19.89 | 2023 | Tandemlife |
| United Therapeutics Corporation | $19.61 | 2025 | Tyvaso |
| Bridgebio Pharma, INC. | $19.11 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $18.96 | 2025 | Inspire |
| Lantheus Medical Imaging, INC. | $16.67 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.18 | 2021 | |
| Atricure, INC. | $15.23 | 2025 | Atriclip Laa Exclusion System |
| Medicomp INC | $14.65 | 2022 | |
| Pulmonx Corporation | $14.60 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Kiniksa Pharmaceuticals, LTD. | $13.48 | 2023 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $12.10 | 2020 | |
| Astellas Pharma US INC | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Bernal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.